Autobio Diagnostics Co., Ltd.

XSSC:603658 Stock Report

Market Cap: CN¥25.7b

Autobio Diagnostics Valuation

Is 603658 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603658 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603658 (CN¥44.99) is trading above our estimate of fair value (CN¥17.3)

Significantly Below Fair Value: 603658 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603658?

Key metric: As 603658 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 603658. This is calculated by dividing 603658's market cap by their current earnings.
What is 603658's PE Ratio?
PE Ratio20.2x
EarningsCN¥1.27b
Market CapCN¥25.74b

Price to Earnings Ratio vs Peers

How does 603658's PE Ratio compare to its peers?

The above table shows the PE ratio for 603658 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.8x
600529 Shandong Pharmaceutical GlassLtd
19.8x18.4%CN¥18.4b
301371 Harbin Fuerjia Technology
21.6x8.4%CN¥15.5b
300595 Autek China
26.4x16.8%CN¥16.7b
688029 Micro-Tech (Nanjing)Ltd
23.5x19.0%CN¥13.0b
603658 Autobio Diagnostics
20.2x20.8%CN¥25.7b

Price-To-Earnings vs Peers: 603658 is good value based on its Price-To-Earnings Ratio (20.2x) compared to the peer average (22.9x).


Price to Earnings Ratio vs Industry

How does 603658's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
603658 20.2xIndustry Avg. 34.5xNo. of Companies14PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 603658 is good value based on its Price-To-Earnings Ratio (20.2x) compared to the CN Medical Equipment industry average (34.5x).


Price to Earnings Ratio vs Fair Ratio

What is 603658's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603658 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.2x
Fair PE Ratio27x

Price-To-Earnings vs Fair Ratio: 603658 is good value based on its Price-To-Earnings Ratio (20.2x) compared to the estimated Fair Price-To-Earnings Ratio (27x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603658 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥44.99
CN¥58.57
+30.2%
9.7%CN¥66.41CN¥51.80n/a5
Dec ’25CN¥46.47
CN¥58.57
+26.0%
9.7%CN¥66.41CN¥51.80n/a5
Nov ’25CN¥45.38
CN¥58.15
+28.1%
9.1%CN¥66.41CN¥51.80n/a6
Oct ’25CN¥48.16
CN¥56.56
+17.4%
8.2%CN¥66.41CN¥52.80n/a6
Sep ’25CN¥40.84
CN¥56.56
+38.5%
8.2%CN¥66.41CN¥52.80n/a6
Aug ’25CN¥40.89
CN¥65.55
+60.3%
3.7%CN¥70.00CN¥62.54n/a6
Jul ’25CN¥45.65
CN¥65.55
+43.6%
3.7%CN¥70.00CN¥62.54n/a6
Jun ’25CN¥51.29
CN¥65.55
+27.8%
3.7%CN¥70.00CN¥62.54n/a6
May ’25CN¥57.02
CN¥64.39
+12.9%
5.7%CN¥70.00CN¥57.41n/a7
Apr ’25CN¥57.84
CN¥60.64
+4.8%
7.9%CN¥67.80CN¥55.40n/a6
Mar ’25CN¥64.10
CN¥59.49
-7.2%
7.4%CN¥67.80CN¥55.40n/a5
Feb ’25CN¥47.71
CN¥59.49
+24.7%
7.4%CN¥67.80CN¥55.40n/a5
Jan ’25CN¥57.01
CN¥58.43
+2.5%
4.3%CN¥62.50CN¥55.40n/a5
Dec ’24CN¥53.48
CN¥59.14
+10.6%
11.2%CN¥73.00CN¥52.20CN¥46.476
Nov ’24CN¥44.31
CN¥59.14
+33.5%
11.2%CN¥73.00CN¥52.20CN¥45.386
Oct ’24CN¥45.73
CN¥63.18
+38.1%
7.5%CN¥73.00CN¥59.57CN¥48.166
Sep ’24CN¥45.74
CN¥63.18
+38.1%
7.5%CN¥73.00CN¥59.57CN¥40.846
Aug ’24CN¥54.65
CN¥73.54
+34.6%
8.1%CN¥82.11CN¥63.00CN¥40.896
Jul ’24CN¥51.73
CN¥73.54
+42.2%
8.1%CN¥82.11CN¥63.00CN¥45.656
Jun ’24CN¥56.18
CN¥73.54
+30.9%
8.1%CN¥82.11CN¥63.00CN¥51.296
May ’24CN¥57.23
CN¥73.65
+28.7%
8.8%CN¥82.11CN¥63.00CN¥57.025
Apr ’24CN¥60.94
CN¥83.38
+36.8%
11.9%CN¥92.00CN¥64.00CN¥57.845
Mar ’24CN¥65.27
CN¥83.38
+27.7%
11.9%CN¥92.00CN¥64.00CN¥64.105
Feb ’24CN¥66.70
CN¥83.38
+25.0%
11.9%CN¥92.00CN¥64.00CN¥47.715
Jan ’24CN¥61.85
CN¥82.06
+32.7%
9.9%CN¥87.75CN¥66.00CN¥57.015
Dec ’23CN¥60.02
CN¥82.06
+36.7%
9.9%CN¥87.75CN¥66.00CN¥53.485

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Autobio Diagnostics Co., Ltd. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sandra SunBofA Global Research
Pei ChengChina Galaxy Securities Co., Ltd.
Jin ZhangChina International Capital Corporation Limited